GlassScriptPhysician profile
Bradley G Neuenschwander
NPI 1174740799
$2,780.19
in general payments reported to CMS, 2019-2025
25 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $264 · 2021: $315 · 2022: $571 · 2023: $648 · 2024: $485 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.95 |
| Education | $194.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $897.66 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $600.34 | 2019-2024 | |
| Janssen Biotech, INC. | $289.64 | 2019-2025 | Tremfya, Simponi, Stelara |
| Leo Pharma INC. | $135.54 | 2022-2025 | Adbry |
| Pfizer INC. | $111.84 | 2019-2023 | |
| Galderma Laboratories, L.P. | $98.63 | 2021-2022 | |
| Biofrontera INC. | $82.46 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $74.59 | 2022-2024 | Taltz, Olumiant |
| Genzyme Corporation | $65.05 | 2019-2021 | |
| Abbott Laboratories | $62.75 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $52.40 | 2023-2024 | Zoryve |
| Strongbridge US INC. | $42.81 | 2019 | |
| Amgen INC. | $37.01 | 2019-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $36.20 | 2023-2025 | Sotyktu |
| Ucb, INC. | $29.96 | 2024 | Bimzelx |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $29.79 | 2024-2025 | Opzelura |
| Almirall LLC | $23.50 | 2025 | Seysara |
| Amarin Pharma, INC. | $17.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $15.63 | 2023 | Dupixent |
| Sun Pharmaceutical Industries INC. | $15.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.05 | 2020 | |
| Dermira, INC. | $13.82 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.70 | 2023 | Spevigo |
| Glaxosmithkline, LLC. | $13.37 | 2021 | |
| Organon LLC | $7.35 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Neuenschwander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.